CC BY-NC-ND 4.0 · Avicenna J Med 2020; 10(04): 249-251
DOI: 10.4103/ajm.ajm_54_20
Case Report

Thyrotoxic periodic paralysis after urethral dilatation

Moayyad Alziadat
Department of Critical Care Medicine, St Joseph’s University Medical Center, Paterson, New Jersey, USA
Mourad Ismail
Department of Critical Care Medicine, St Joseph’s University Medical Center, Paterson, New Jersey, USA
› Institutsangaben

Verantwortlicher Herausgeber dieser Rubrik: Financial support and sponsorship Nil.


Thyrotoxic periodic paralysis (TPP) is a rare and serious manifestation of thyrotoxicosis that causes flaccid paralysis. In severe cases, it can be life-threatening due to respiratory failure and cardiac arrhythmias. TPP is due to increased sodium/potassium ATPase activity during thyrotoxic states, which is due to mutations encoding potassium channels. It is precipitated by situations that cause a surge in catecholamines, insulin, or both. It can be treated with potassium supplementation and nonselective beta blockers, and it can be prevented by establishing euthyroid state. With the increasing numbers of outpatient procedures performed nowadays and the stress related to these procedures, patients with TPP may develop paralysis after these procedures, so clinicians should be aware of this condition and the importance of identifying it in patients presenting with flaccid paralysis.


Artikel online veröffentlicht:
04. August 2021

© 2020. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

  • References

  • 1 Vijayakumar A, Ashwath G, Thimmappa D. Thyrotoxic periodic paralysis: Clinical challenges. J Thyroid Res 2014; 2014: 649502
  • 2 Okinaka S, Shizume K, Iino S, Watanabe A, Irie M, Noguchi A. et al. The association of periodic paralysis and hyperthyroidism in Japan. J Clin Endocrinol Metab 1957; 17: 1454-9
  • 3 Kung AW. Thyrotoxic periodic paralysis: A diagnostic challenge. J Clin Endocrinol Metab 2006; 91: 2490-5
  • 4 Ghalyoun BA, Khaddash I, Shamoon D, Shaaban H, Hanna M, Tiyyagura S. et al. A rare case of hypokalemic ventricular tachycardia in a patient with thyrotoxic periodic paralysis. Int J Crit Illn Inj Sci 2019; 9: 199-202
  • 5 Lam L, Nair RJ, Tingle L. Thyrotoxic periodic paralysis. Proc (Bayl Univ Med Cent) 2006; 19: 126-9
  • 6 Paul B, Hirudayaraj P, Baig MW. Thyrotoxic periodic paralysis: An unusual presentation of weakness. Emerg Med J 2003; 20: E7
  • 7 Ryan DP, da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AW. et al. Mutations in potassium channel kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell 2010; 140: 88-98
  • 8 Melo MCC, de Souza JS, Kizys MML, Vidi AC, Dorta HS, Kunii IS. et al. Novel lincRNA susceptibility gene and its role in etiopathogenesis of thyrotoxic periodic paralysis. J Endocr Soc 2017; 1: 809-15